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Abstract Resistance to chemotherapy is a major problem in
the treatment of urothelial bladder cancer. Several mecha-
nisms have been identified in resistance to doxorubicin by
analysis of resistant urothelial carcinoma (UC) cell lines,
prominently activation of drug efflux pumps and diminished
apoptosis. We have derived a new doxorubicin-resistant cell
line from BFTC-905 UC cells, designated BFTC-905-
DOXO-II. A doxorubicin-responsive green fluorescent pro-
tein (GFP) reporter assay indicated that resistance in BFTC-
905-DOXO-II was not due to increased drug efflux pump
activity, whereas caspase-3/7 activation was indeed dimin-
ished. Gene expression microarray analysis revealed changes
in proapoptotic and antiapoptotic genes, but additionally in-
duction of the mevalonate (cholesterol) biosynthetic pathway.
Treatment with simvastatin restored sensitivity of BFTC-905-
DOXO-II to doxorubicin to that of the parental cell line.
Induction of the mevalonate pathway has been reported as a
mechanism of chemoresistance in other cancers; this is the
first observation in bladder cancer. Combinations of statins
with doxorubicin-containing chemotherapy regimens may
provide a therapeutic advantage in such cases.
Keywords Bladder cancer . Chemotherapy . Doxorubicin
resistance .Mevalonate pathway
Introduction
Bladder cancer represents the fifth most common malignancy
worldwide with an annual incidence of at least 386,000 cases
and an annual mortality approaching 150,000 cases [1]. The
fatal outcome results mainly from advanced muscle-invasive
tumours progressing to metastatic disease; such tumours can
develop either from flat dysplastic carcinoma in situ lesions or
by progression of otherwise prognostically favourable super-
ficial papillary tumours [2, 3]. Two combination chemothera-
peutic regimens dominate the systemic treatment of advanced
urothelial carcinoma, with methotrexate, vinblastine,
adriamycin and cisplatin (M-VAC) being more and more
replaced by the comparably efficient but less toxic
gemcitabine and cisplatin (GC) combination [4, 5]. With both
combination chemotherapy regimens, nevertheless, response
rates barely exceed 50 %, implying mechanisms of primary
chemoresistance operating in at least half of the tumours [6].
Moreover, clinical responses are rarely durable or even cura-
tive, which could be explained either by selection of pre-
existing chemoresistant cells or by development of secondary
drug resistance during the treatment. Several other chemother-
apeutic combinations have been formulated to combat the
failure of M-VAC or GC, like a combination of paclitaxel
and doxorubicin [7] or paclitaxel and gemcitabine [8];
their clinical efficiency is, nevertheless, rather limited.
The microtubule inhibitor vinflunin is the only agent to
date with a proven, if moderate, clinical benefit in
second-line chemotherapy [9].
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With regard to doxorubicin, which is applied either as part
of the M-VAC (=adriamycin) scheme or in combination with
paclitaxel, several experimental chemoresistance models have
been established. Their molecular analysis yielded an en-
hanced drug efflux as a major chemoresistance mechanism,
either alone [10–12] or in association with a partial or com-
plete loss of the therapeutic target, DNA topoisomerase II [13,
14], or with a concomitant activation of antiapoptotic signal-
ling pathways [15]. The analysis of clinical tumours, while
corroborating the clinical significance of increased expression
of drug efflux pumps like ABCB1 (MDR-1) or ABCC1
(MRP), suggested nevertheless that this is unlikely to repre-
sent the only resistance mechanism [16–19]. Here, we de-
scribe the establishment of a new cell culture model of doxo-
rubicin resistance in bladder cancer and its molecular analysis.
We observed mevalonate pathway activation that might en-
gender substantial doxorubicin chemoresistance without the
involvement of drug efflux. Importantly, pharmacologic inhi-
bition of the pathway completely abolished this novel type of
therapy resistance. In view of a recent intensive debate about
the pharmacological application of mevalonate synthesis in-
hibitors—statins—in cancer treatment [20–22], this new ex-
perimental model could be instrumental in formulating a new




The human well-differentiated papillary bladder carcinoma
cell line BFTC-905 [23] was obtained from the German
Collection of Microorganisms and Cell Cultures (DSMZ,
Braunschweig, Germany). The clonally related cell lines
RT112 and RT112/D21 [12] were a generous gift from Dr.
M.S. Michel (Department of Urology, Mannheim Medical
Center, Mannheim, Germany). The cells were cultured in
high-glucose (4.5 g/l) Dulbecco’s modified Eagle’s medium
(DMEM) (Gibco–Invitrogen, Mannheim, Germany) supple-
mented with 10 % foetal bovine serum (FBS) (Biochrom AG,
Berlin, Germany), penicillin (100 U/ml) und streptomycin
(100 μg/ml, Biochrom AG) at 37 °C with 5 % CO2. The
clonally related cell lines UM-UC-6 and UM-UC-6dox [10,
11] were a generous gift from Dr. H.B. Grossman (MD
Anderson Cancer Center, Houston, USA) and were cultured
identically except that minimal essential medium (MEM)
(Gibco–Invitrogen) was used instead of DMEM. Routine
subculturing was performed after short-term incubation with
0.05 % trypsin in 0.02 % EDTA in phosphate-buffered saline
(PBS) (Biochrom AG). The daughter cell line BFTC-905–
DOXO-II was derived from a single colony obtained after
intermittent doxorubicin (Calbiochem, Darmstadt, Germany)
treatment, starting from 100 nM and terminating with 300 nM
over a period of 2 months.
Viability and apoptosis assays
To determine cell viability after doxorubicin treatment, the
CellTiter-Glo luminescent cell viability assay (Promega,
Mannheim, Germany) was used. Apoptosis was followed
using the Caspase-Glo 3/7 assay by the same company ac-
cording to the manufacturer’s instructions. The effects of
doxorubicin treatment on BFTC-905 and its doxorubicin-
resistant daughter cell line BFTC-905–DOXO-II were deter-
mined by two approaches. To measure acute toxicity, 3×103
cells were seeded in triplicate wells of a 96-well plate and
allowed to adhere overnight. Growth medium containing a
range of doxorubicin concentrations was applied the next day,
and cell viability was assessed after a further 4 days of incu-
bation. Drug effects were expressed as the percentage of
viability loss relative to untreated control cells. The half-
maximal inhibitory concentration (IC50) was then determined
graphically from the dose–response curve. To measure chron-
ic toxicity, a clonogenic assay was performed after incubating
the parental or the daughter cell line with doxorubicin at their
respective IC50 dose for 8 days and further incubation for
3 weeks in doxorubicin-free culture medium. To investigate
combined effects of simvastatin (Sigma Aldrich, Munich,
Germany) and doxorubicin, 25,000 cells/well from BFTC905
or BFTC905 Doxo 550 were plated in 24-well plates. The
next day, the medium was changed and the cells were treated
with 1–30 mM simvastatin, 25–400 nM doxorubicin or a
combination of both compounds. After 24 h, 50-μl MTT
reagent was added and the cells were incubated for 30 min
at 37 °C. The cells were then lysed with 500 μl DMSO and
transferred into 96 wells. Each experiment was performed in
quadruplicates with an ELISA reader at 570 nm/620 nm.
Analysis of the mechanism of chemoresistance
BFTC-905, BFTC-905-DOXO-II, RT112, RT112/D21, UM-
UC-6 or UM-UC-6dox was seeded on 100-mm diameter cell
culture dishes (3×106 cells in 10ml) and transfected with 6 μg
of the pE9ns2GFP plasmid [24] on the next day. Transfections
were carried out with the FuGENE 6 Transfection Reagent
(Roche Applied Science, Basel, Switzerland) following the
manufacturer’s instructions. Transfections were left for 36 h
and then split into two 60-mm cell culture dishes. One dish
was left with standard growth medium, while the other one
was incubated with medium containing 1 μM doxorubicin for
48 h. Green fluorescent protein (GFP) induction was then
determined as the fold increase of GFP-positive cells after
doxorubicin treatment, as described previously [24, 25].
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Microarray gene expression profiling
Gene expression microarray analysis and evaluation were
performed with independent triplicate RNA preparations from
each cell line using HG U133A GeneChips (Affymetrix,
Berlin, Germany) as described previously [26]. For functional
annotation, the Database for Annotation, Visualization and
Integrated Discovery (DAVID), version v6.7, was used [27].
Statistical analysis
The statistical significance of differences in clonogenicity and
apoptotic response, respectively, was evaluated by the
Wilcoxon signed-rank test. A p value of 0.05 was taken to
indicate statistical significance.
Results
Derivation of the BFTC-905-DOXO-II daughter cell line
Applying a doxorubicin treatment regimen starting with
100 nM and terminating with 300 nM over a period of
2 months, five discrete colonies survived out of a nearly
confluent starting culture. One of the clones was further
expanded and analyzed in more detail (Fig. 1).
Acute and chronic toxicity of doxorubicin treatment
Initial analysis of acute doxorubicin toxicity revealed that
doxorubicin resistance of the BFTC-905-DOXO-II daughter
cell line is rather modest, with an IC50 value of 450 nM, as
compared to 150 nM in the parental cell line. In both cell lines,
doxorubicin treatment at IC50 for 4 days engendered a long-
term culture depression, with continuous diminution of viable
cell numbers over a period of the next 3 weeks. During this
crisis, both apoptotic and senescent cells could readily be
observed. Then, growth restoration began with morphologi-
cally distinct islands of small and very compactly arranged
cells. Indeed, in clonogenicity assays of cell cultures in this
phase of growth restoration, the overall clonogenicity de-
creased rather sharply with the parental cell line, whereas it
increased by 35 % with the daughter cell line (Fig. 2), provid-
ing an additional expression of its relative doxorubicin
resistance.
Atypical mechanism of resistance of BFTC-905-DOXO-II
cells
In two previously published doxorubicin-resistant cell lines,
RT112/RT112-D21 [12] and UM-UC6/UM-UC-6dox [10,
11], the mechanism underlying resistance was identified as
classical multidrug resistance by overexpressed ABC efflux
transporters. To investigate whether the same mechanism was
responsible in the BFTC-905-DOXO-II daughter cell line, we
employed the previously described doxorubicin-responsive
reporter plasmid pE9ns2GFP, which harbours the GFP report-
er gene under the control of a synthetic promoter that is
strongly activated by intracellular doxorubicin [24, 25].
Therefore, cells with overactive ABC efflux transporters dis-
play lower GFP fluorescence under doxorubicin treatments.
Indeed, activation of the GFP reporter gene by doxorubicin
treatment was substantially lower in the respective resistant
daughter cell line than in the parental cell line for both control
pairs RT112/RT112-D21 and UM-UC6/UM-UC-6dox
(Fig. 3). Remarkably, in the BFTC-905 and BFTC-905-
DOXO-II cell lines, GFP activation was actually stronger in
the doxorubicin-resistant daughter cell line, excluding wide-
spread overexpression of drug efflux pumps as a mechanism
of resistance (Fig. 3). Deficient apoptosis was a logical next
candidate, and indeed, we found that activation of caspase-3/7
in the wake of doxorubicin treatment was greatly compro-
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Fig. 1 Microscopic
documentation of the response of
BFTC-905-DOXO-II cells to
doxorubicin. Doxorubicin was
applied for 96 h in the
concentrations indicated, and




Expression profiling reveals activation of the mevalonate
pathway as a probable mechanism of doxorubicin resistance
in BFTC-905-DOXO-II cells
To clarify the mechanisms of resistance in more detail, we
compared global gene expression profiles of BFTC905 paren-
tal cells with the doxorubicin-resistant daughter cell lines
BFTC905-DOXO-II by microarray analysis using Affymetrix
arrays.
Overall, 227 annotated genes were found significantly
upregulated and 213 genes were downregulated in the resis-
tant cells (Suppl. Table 1). According toGO analysis (Table 1),
these genes were involved in ectoderm, epithelium or
epidermis development; regulation of apoptosis, programmed
cell death or cell death; sterol or steroid biosynthetic process-
es; and response to vitamins. An analysis by tissue distribution
showed that the changes in genes involved in epithelium
development reflected the downregulation of genes expressed
in keratinocytes, whereas genes expressed in the urothelium
were rather upregulated. Both proapoptotic and antiapoptotic
genes were differentially expressed. Strikingly, all genes cat-
egorized as involved in sterol biosynthesis were upregulated,
and all their products catalyze intermediate steps of cholester-
ol biosynthesis. The largest group of the genes categorized as
“response to vitamins” is involved in responses to vitamin A






























Fig. 2 Activation of clonogenic cells by doxorubicin treatment in BFTC-
905-DOXO-II cells, but not in the parental cell line. Number of clones
from BFTC-905 or BFTC-905-DOXO-II cells following treatment with
doxorubicin. There was no statistical difference in the overall
clonogenicity in untreated cultures. In the parental cell line, the
clonogenicity decreased by 88 % in the doxorubicin-treated cultures
(p=0.0022). Simultaneously, the overall clonogenicity increased by
35 % in the doxorubicin-selected daughter cell line (p=0.31). The
difference in clonogenicity between the doxorubicin-treated parental



































Fig. 3 Doxorubicin resistance in BFTC-905-DOXO-II cells does not
involve doxorubicin efflux. The ability to actively efflux doxorubicin
was assayed via a doxorubicin-activated GFP reporter, in parallel with
bladder cancer cell lines with multidrug resistant (MDR) phenotype. The
fold increase in GFP-positive cells after incubation with 1 μM
doxorubicin is shown. Whereas GFP activation by doxorubicin was
distinctly lower in MDR daughter cell lines RT112/D21 and UM-UC-
6dox than in their respective parental cell lines RT112 and UM-UC-6,
there was even an increase in GFP activation in BFTC-905-DOXO-II
cells in comparison to that in the BFTC-905 parental cell line
Tumor Biol.
Statin treatment reverses doxorubicin resistance
in BFTC-905-DOXO-II cells
As the microarray data indicated an upregulation of the cho-
lesterol biosynthesis pathway in the doxorubicin-resistant cell
line BFTC-905-DOXO-II, we investigated its possible in-
volvement in resistance to doxorubicin by blocking the key
enzyme HMG-CoA reductase by the inhibitor simvastatin. In
a short-term assay, the IC50 was approximately 50 nM for
doxorubicin in standard BFTC-905 cells, whereas the resistant
daughter cell line had an IC50 (DOXO) of 400 nM (Fig. 5a).
Interestingly, the two cell lines differed in their IC50 values
for simvastatin, with BFTC-905-DOXO-II being less
sensitive (Fig. 5b). Combined treatment with simvastatin
and doxorubicin enhanced cell death in both cell lines
(Fig. 5c, d), and in the presence of simvastatin, both











































Fig. 4 Reduced apoptotic
response in BFTC-905-DOXO-II
cells. Activity of caspase-3/7 in
doxorubicin-treated BFTC-905
cells (215 % compared with
untreated cultures, p=0.0079) and
BFTC-905-DOXO-II cells where
the 39 % increase in activity was
not significant (p=0.08).
Table 1 Categories of genes differentially expressed in doxorubicin-resistant BFTC905 cells
Term p value Genes FDR
GO:0007398—ectoderm development 4.30E+09 KRT6A, KRT6B, S100A7, FST, GJB3, JAG1, SOX9, LAMB3, LAMA3, KRT5,
KRT17, SPRR1A, SPRR1B, KRT14, SPRR3, DSP, EMP1, KLF4
0.0075
GO:0042981—regulation of apoptosis 1.14E+11 ITGB3BP, BID, HTATIP2, RBM5, SOX4, BNIP3, SOX9, TIMP3, MAGED1,
PEA15, ERCC5, MYD88, CASP4, BAG1, ALDH1A3, RHOA, IL1B, HSPE1,
HSPA5, CD24, NQO1, MYC, PHLDA1, IRAK1, HERPUD1, VAV3, ROCK1,
EEF1A2, LGALS1, KLF10, MBD4, HBXIP, GAL, CDK5, DAPK3, PPIF,
PLA2G4A, ADRB2, BNIP3L, AVEN
0.0198
GO:0016126—sterol biosynthetic process 1.36E+11 HMGCR, CYP51A1, SQLE, DHCR7, HMGCS1, IDI1, FDFT1, SC4MOL 0.0237
GO:0043067—regulation of programmed
cell death
1.41E+11 ITGB3BP, BID, HTATIP2, RBM5, SOX4, BNIP3, SOX9, TIMP3, MAGED1,
PEA15, ERCC5, MYD88, CASP4, BAG1, ALDH1A3, RHOA, IL1B, HSPE1,
HSPA5, CD24, NQO1, MYC, PHLDA1, IRAK1, HERPUD1, VAV3, ROCK1,
EEF1A2, LGALS1, KLF10, MBD4, HBXIP, GAL, CDK5, DAPK3, PPIF,
PLA2G4A, ADRB2, BNIP3L, AVEN
0.0246
GO:0010941—regulation of cell death 1.54E+10 ITGB3BP, BID, HTATIP2, RBM5, SOX4, BNIP3, SOX9, TIMP3, MAGED1,
PEA15, ERCC5, MYD88, CASP4, BAG1, ALDH1A3, RHOA, IL1B, HSPE1,
HSPA5, CD24, NQO1, MYC, PHLDA1, IRAK1, HERPUD1, VAV3, ROCK1,
EEF1A2, LGALS1, KLF10, MBD4, HBXIP, GAL, CDK5, DAPK3, PPIF,
PLA2G4A, ADRB2, BNIP3L, AVEN
0.0269
GO:0033273—response to vitamin 2.12E+10 MICB, PLA2G4A, CCND1, BMP2, TFRC, MAP1B, IL1B, TIMP3, KLF4, SPP1 0.0369
GO:0060429—epithelium development 2.44E+11 BMP2, S100A7, DHRS9, JAG1, GREM1, GSTM3, LAMA3, KRT5, SPRR1A,
ALDH1A3, SPRR1B, UPK1B, KRT14, SPRR3, DSP, PBX1, CA2, EMP1
0.0425
GO:0008544—epidermis development 2.75E+11 S100A7, FST, GJB3, JAG1, SOX9, LAMB3, LAMA3, KRT5, KRT17, SPRR1A,
SPRR1B, KRT14, SPRR3, DSP, EMP1, KLF4
0.0479





In the present study, we report the establishment of a new cell
culture model of doxorubicin resistance in urothelial bladder
carcinoma. As measured by a specific reporter gene system, the
resistant daughter cell line showed a higher response to intracel-
lular doxorubicin, excluding drug efflux as the major resistance
mechanism. This is unexpected, as this was a dominant mech-
anism in previously established cell lines [10–15]. In accordance
with other reports, however, the resistance was associated with a
diminished apoptotic response to doxorubicin. To unravel the
underlying molecular mechanism, we performed global gene
expression profiling and discovered a permanent overexpression
of multiple enzymes of the mevalonate pathway in the resistant
daughter. Accordingly, simvastatin treatment restored doxorubi-
cin sensitivity to the level of the parental cell line.
Mevalonate pathway overactivation is a frequent event in
carcinogenesis [20–22], and the rate-limiting enzyme of the
pathway, 3-hydroxy 3-methylglutaryl coenzyme A reductase
(HMGCR), has been even classified as a metabolic oncogene
[28]. The consequences of mevalonate pathway activation can
be relevant not only for cancer development per se, but also
for therapy response. Several mechanisms may contribute,
reflecting different outputs of the pathway [20–22]. One of
these is isoprenylation of Ras, Rac and Rho oncoproteins,
which is crucial for their membrane localization and subse-
quent signal transduction. Activation of the according branch
of the mevalonate pathway therefore contributes not only to
cancer development, but also resistance to cytotoxic and
targeted therapies [29]. Another important output of the
mevalonate pathway is cholesterol, which is both a stable
constituent of biological membranes and a precursor for ste-
roid hormones. Cholesterol content can exert profound effects
on physical and chemical properties of biomembranes.
Mevalonate pathway overactivation can result in an increase
of cholesterol content in mitochondrial membranes of hepa-
tocellular carcinoma (HCC) cells, thereby reducing their apo-
ptotic response to doxorubicin [30]. Indeed, the mevalonate
pathway activation constitutes a sort of cell defence (immedi-
ate adaptive response) of acute leukaemia (AML) cells ex-
posed to chemotherapeutic drugs [31]. We are not aware of
any report describing mevalonate pathway overactivation in
bladder cancer. In view of the limited therapeutic efficacy of
current chemotherapeutic regimens [6] and the inability to
explain the intrinsic and acquired urothelial carcinoma doxo-
rubicin resistance by increased drug efflux alone [16–19], our
finding calls for a more intense investigation of the function of









































Fig. 5 Simvastatin reverts doxorubicin resistance in BFTC-905-DOXO-II cells. The simultaneous treatment with doxorubicin and simvastatin abolishes
differences in chemosensitivity between the parental BFTC-905 and daughter BFTC-905-DOXO-II cells
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In particular, if mevalonate pathway activation should be a
critical factor in bladder cancer development and therapy
resistance, it would offer a novel pharmacological target.
Statins are a group of natural and synthetic inhibitors of the
HMGCR. They are widely prescribed, especially to lower
cholesterol levels in serum [20–22]. Statin use for cancer
treatment is intensively debated. In various circumstances,
statins were found to cooperate with anticancer drugs, increas-
ing the effects of cetuximab in colorectal cancer cells [32], of
gefitinib in NSCLC cells [33] and of doxorubicin in HCC cell
lines [30]. Pravastatin was even successfully incorporated into
an experimental induction chemotherapy regimen of AML
[34]. Interestingly, the cooperation of statins with doxorubicin
may be partly based on an off-target effect on multidrug efflux
pumps, as reported e.g. for neuroblastoma [35] or rhabdomyo-
sarcoma [36] cells. With regard to urothelial bladder carcino-
ma cells, this is, to our knowledge, the first report showing a
clear therapeutic cooperativity of a statin with a conventional
anticancer drug. Which of the mechanisms outlined above is
responsible for the cooperation of simvastatin and doxorubi-
cin in our model system awaits further analysis. Our data,
however, argue against an effect via multidrug efflux pump
targeting, as the doxorubicin resistance of BFTC-905-DOXO-
II cells is clearly not based on activated drug efflux.
Of note, despite the clear biological rationale, chronic statin
use is not always cancer-protective. Especially for bladder
cancer, the results are conflicting [37–39]. Another complica-
tion is a substantial interindividual heterogeneity in therapeu-
tic response to statins [20]. Cell line collections have been
used to define the biological basis of statin sensitivity in
multiple myeloma [40] and breast carcinoma [41], and we
believe that our pair of cell lines could be similarly helpful
within the context of urothelial carcinoma. Statin use for
cancer treatment thus follows the personalized treatment
paradigm. With that reservation, our results may open the
way to rational statin use in urothelial cancer treatment.
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